Cargando…

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lieverse, Relinde I. Y., Marcus, Damiënne, van der Wiel, Alexander M. A., Van Limbergen, Evert J., Theys, Jan, Yaromina, Ala, Lambin, Philippe, Dubois, Ludwig J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332215/ https://www.ncbi.nlm.nih.gov/pubmed/32386436 http://dx.doi.org/10.1002/1878-0261.12705

Ejemplares similares

Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
por: Marcus, Damiënne, et al.
Publicado: (2021)

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer
por: Sanduleanu, Sebastian, et al.
Publicado: (2020)

Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
por: Olivo Pimentel, Veronica, et al.
Publicado: (2021)

Combining radiotherapy with immunotherapy: the past, the present and the future
por: Van Limbergen, Evert J, et al.
Publicado: (2017)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology
por: van der Wiel, Alexander M. A., et al.
Publicado: (2022)

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
por: van Kuijk, Simon J. A., et al.
Publicado: (2016)

Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape
por: Hamis, Sara, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
por: Panth, Kranthi Marella, et al.
Publicado: (2016)

Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer
por: Prades-Sagarra, Èlia, et al.
Publicado: (2023)

Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy
por: Kubiak, Aleksandra M., et al.
Publicado: (2021)

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
por: Martín-Otal, Celia, et al.
Publicado: (2022)

Expression of Fibronectin Isoforms in Human Breast Tissue: Production of Extra Domain A(+)/Extra Domain B(+) by Cancer Cells and Extra Domain A(+) by Stromal Cells
por: Matsumoto, Ei‐ichi, et al.
Publicado: (1999)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Use of a Luciferase-Expressing Orthotopic Rat Brain Tumor Model to Optimize a Targeted Irradiation Strategy for Efficacy Testing with Temozolomide
por: Mowday, Alexandra M., et al.
Publicado: (2020)

Fibronectin Extra Domain A Promotes Liver Sinusoid Repair following Hepatectomy
por: Sackey-Aboagye, Bridget, et al.
Publicado: (2016)

Correction: Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Publicado: (2022)

CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B
por: Zhang, Zhijie, et al.
Publicado: (2022)

Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells
por: Sosa Iglesias, Venus, et al.
Publicado: (2018)

Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma
por: Saw, Phei Er, et al.
Publicado: (2021)

Lack of Fibronectin Extra Domain A Alternative Splicing Exacerbates Endothelial Dysfunction in Diabetes
por: Gortan Cappellari, Gianluca, et al.
Publicado: (2016)

Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?
por: Vanneste, Ben G. L., et al.
Publicado: (2016)

A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn’s disease
por: Vanneste, Ben G.L., et al.
Publicado: (2018)

The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy
por: van Kuijk, Simon J. A., et al.
Publicado: (2016)

Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent
Publicado: (1989)

MRI of Breast Tumor Initiating Cells Using the Extra Domain-B of Fibronectin Targeting Nanoparticles
por: Sun, Yujin, et al.
Publicado: (2014)

Fibroblast-like synovial cell production of extra domain A fibronectin associates with inflammation in osteoarthritis
por: Kragstrup, Tue W., et al.
Publicado: (2019)

Fibronectin extra domain a limits liver dysfunction and protects mice during acute inflammation()
por: Venu, Vivek Krishna Pulakazhi, et al.
Publicado: (2023)

Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis
por: Moreno Roig, Eloy, et al.
Publicado: (2018)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

Chronic radiation proctitis: tricks to prevent and treat
por: Vanneste, Ben G. L., et al.
Publicado: (2015)

Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial
por: Reymen, Bart J.T., et al.
Publicado: (2019)

Fibronectin containing alternatively spliced extra domain A interacts at the central and c-terminal domain of Toll-like receptor-4
por: Gupta, Shubhangi, et al.
Publicado: (2022)

Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells
por: Kazokaitė, Justina, et al.
Publicado: (2018)

Fibronectin extra domain A (FN-EDA) causes glaucomatous trabecular meshwork, retina, and optic nerve damage in mice
por: Mavlyutov, Timur A., et al.
Publicado: (2022)

Cellular Fibronectin Containing Extra Domain A Causes Insulin Resistance via Toll-like Receptor 4
por: Rajak, Sangam, et al.
Publicado: (2020)

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lbfeev6m35bfe5dco15h0cie44